Skip to main content
Fig. 3 | BMC Urology

Fig. 3

From: A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinoma

Fig. 3

Network diagrams of outcome indicators. (A) Disease-free survival (DFS); (B) Overall survival (OS); (C) Recurrence-free survival (RFS); (D) adverse events (AEs). Pla, placebo; Suni, sunitinib; Sora, sorafenib; Niv + Ipi, nivolumab + ipilimumab; IL2 + IFN + 5FU, interleukin-2 + interferon-alpha2a + 5-fluorouracil; Atez, atezolizumab; Pazo, pazopanib; Pemb, pembrolizumab; Gire, girentuximab; Teg + Ura, tegafur + uracil; Thal, thalidomide; Axit, axitinib

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us